Infojustice – US, Canadian & Mexican Law Professors, Academics And Policy Experts: NAFTA Must Include Fair Use, Safe Harbors 15/11/2017 by Intellectual Property Watch 1 Comment WASHINGTON – Today, over seventy international copyright law experts called for NAFTA and other trade negotiators to support a set of balanced copyright principles. The experts urge trade negotiators to support policies like fair use, safe harbor provisions, and other exceptions and limitations that permit and encourage access to knowledge, flourishing creativity, and innovation. Signatories include preeminent intellectual property professors and experts from law schools, think tanks, and public interest organizations in the U.S., Canada, and Mexico, as well as Argentina, Australia, China, Ireland, and Switzerland.
USPTO’s Revised Patent Fee Schedule Raises Price Of IPR Process 14/11/2017 by Intellectual Property Watch 1 Comment The United States Patent and Trademark Office (USPTO) today issued changes to some patent fees, including increases in certain areas, including the cost of using the inter partes review process. Following feedback from users, the office went with some proposed increases, while keeping others at existing levels despite proposals to increase them, it said.
Next Global Congress On IP And The Public Interest 13/11/2017 by Intellectual Property Watch Leave a Comment American University Washington College of Law (AUWCL) Program on Information Justice and Intellectual Property has announced the hosting of Fifth Global Congress on Intellectual Property and the Public Interest, from 27-29 September 2018. And it is now actively seeking sponsors, partners and expressions of interest.
WIPO Vaccines Report Contestable, With UN High-Level Panel Misquoted, Advocate Says 10/11/2017 by Intellectual Property Watch Leave a Comment The World Intellectual Property Organization this week held an event that delved into research, markets and access for vaccines with panels that showed unusual breadth of representation for the UN IP agency. But health advocates have taken issue with the wording of a report released by WIPO at the event.
South Centre: Clear Rules Needed On Biosimilars Equivalence To Help Market Entry, Lower Prices 09/11/2017 by Intellectual Property Watch Leave a Comment As soon as 2022, biological drugs made from active protein substances are expected to make up 50 percent of the pharmaceutical market, as they are increasingly used to treat a number of illnesses such as diabetes, cancer and hepatitis. But with the high price of therapeutics and difficulty in producing biologically similar products, and with the originator products now coming off patent, regulation is of high importance, says a new report from the intergovernmental South Centre.
Geneva Buzzing With Ideas And Events For International Entrepreneurship Week 09/11/2017 by Intellectual Property Watch Leave a Comment A weeklong event next week has been co-organised and sponsored by a number of Geneva actors, such as the World Intellectual Property Organization, the European Organization for Nuclear Research (CERN), and the University of Geneva, as well as lesser known groups and projects, to celebrate the international week of entrepreneurship.
MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug 31/10/2017 by Intellectual Property Watch 1 Comment Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, dropping prices dramatically.
FAO Calls On WTO Ministerial Conference To Protect Small Farmers 25/10/2017 by Intellectual Property Watch Leave a Comment As the biennial World Trade Organization Ministerial Conference is drawing closer, a number of stakeholders are pushing for their priorities to be heard. For its part, the Food and Agriculture Organization of the United Nations (FAO) has called on WTO members to protect smallholder farmers.
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 by Intellectual Property Watch 11 Comments A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment.
No Progress On WTO Appellate Body Appointments As Ranks Thinning 25/10/2017 by Intellectual Property Watch 2 Comments The imbroglio which might cause a major impediment to the World Trade Organization’s functioning is thickening as the United States continues to block the selection process to fill vacancies in the WTO Appellate Body, according to sources.